import mitochondrialProtocolCover from "@assets/mitochondrial-protocol-blog-cover.png";
import peptideProtocolsCover from "@assets/peptide-protocols-blog-cover.png";
import retatrutideCover from "@assets/retatrutide-research-blog-cover.png";
import orforglipronCover from "@assets/orforglipron-blog-cover.png";
import homeostasisCover from "@assets/cellular-homeostasis-blog-cover.png";
import ghkCuCover from "@assets/ghk-cu-blog-cover.png";
import bpcTbCover from "@assets/bpc157-tb500-blog-cover.png";
import nadLongevityCover from "@assets/nad-longevity-blog-cover.png";

export interface BlogPost {
  slug: string;
  title: string;
  excerpt: string;
  date: string;
  category: string;
  image: string;
  content: string;
}

export const blogPosts: BlogPost[] = [
  {
    slug: "peptide-protocols-dosing-reconstitution-benefits",
    title: "Peptide Protocols, Dosing, Reconstitution and Benefits — Complete Guide",
    excerpt: "A comprehensive reference covering reconstitution math, GLP-1 agonists, growth hormone secretagogues, IGF axis peptides, tissue repair compounds, neuro/mood peptides, sexual function, and immune modulators with full dosing protocols.",
    date: "February 20, 2026",
    category: "Peptide Resources",
    image: peptideProtocolsCover,
    content: `
### Introduction

This comprehensive guide covers peptide protocols, dosing, reconstitution, and benefits across all major categories. Originally compiled by Malice.lifts (200k+ on TikTok), this resource is for **education only and is not medical advice**.

---

### Universal Reconstitution Math (Cheat Sheet)

1. Add bacteriostatic water slowly down the glass wall.
2. **Concentration = vial mg / mL BW.** Example: 10 mg vial + 2 mL BW → 5 mg/mL.
3. U100 insulin syringe: 1 unit = 0.01 mL. If 10 mg + 2 mL → 1 unit = 50 mcg.

**Common setups:**

| Vial Size | BW Added | Concentration | Per Unit |
|-----------|----------|---------------|----------|
| 5 mg | 2 mL | 2.5 mg/mL | 1 unit = 25 mcg |
| 5 mg | 2.5 mL | 2 mg/mL | 1 unit = 20 mcg |
| 10 mg | 2 mL | 5 mg/mL | 1 unit = 50 mcg |
| 10 mg | 5 mL | 2 mg/mL | 1 unit = 20 mcg |

---

## GLP-1 Agonists and Weight Management

### Semaglutide

**Overview:** GLP-1 receptor agonist that slows gastric emptying, increases satiety, improves insulin dynamics.

**Benefits:** Appetite control, weight reduction, improved glycemic markers.

**Dosing:** 0.25 mg weekly. Titrate by 0.25–0.5 mg each 2–4 weeks toward 0.5–2.4 mg weekly as tolerated.

**Cycle:** Ongoing; reassess every 8–12 weeks.

**Administration:** Subcutaneous (abdomen, thigh, upper arm).

**Reconstitution:** Typical 5–30 mg vial. Add 2–5 mL BW to reach convenient units (e.g., 10 mg + 2 mL → 1 unit = 50 mcg).

**Stacks:** High protein diet, lifting, steps. If GI upset, split dose or add BPC-157 for GI support.

**Cautions:** Nausea, vomiting, dehydration risk; avoid with history of medullary thyroid carcinoma; escalate slowly.

---

### Tirzepatide

**Overview:** Dual GLP-1 and GIP agonist; stronger appetite suppression and metabolic effects than single agonists.

**Benefits:** Significant weight loss, improved insulin sensitivity, reduced cravings.

**Dosing:** 2.5 mg weekly start; titrate 5–15 mg weekly as tolerated.

**Cycle:** Ongoing; reassess at 12–16 weeks.

**Administration:** Subcutaneous.

**Reconstitution:** 10–50 mg vials common. Example: 10 mg + 2 mL → 1 unit = 50 mcg.

**Stacks:** Lifestyle: high protein, training, sleep. Add BPC-157 if GI irritation occurs.

**Cautions:** GI effects; monitor for hypoglycemia when combined with other agents.

---

### Retatrutide

**Overview:** Triple agonist at GLP-1, GIP, and glucagon receptors; combines satiety with potential thermogenic effects.

**Benefits:** Rapid body weight reduction and appetite control; early clinical promise.

**Dosing:** 0.25–0.5 mg weekly start; titrate toward 1–2 mg weekly as tolerated.

**Cycle:** Ongoing; evaluate response at 8–12 weeks.

**Administration:** Subcutaneous.

**Reconstitution:** Common 10 mg vial. Add 2–5 mL BW to desired concentration.

**Stacks:** Protein forward diet, resistance training. Consider electrolytes for nausea support.

**Cautions:** Similar GI effects as GLP-1 class; watch for increased heart rate.

---

### AOD-9604

**Overview:** Fragment of human growth hormone (176–191) that may increase lipolysis without classic GH effects.

**Benefits:** Body fat reduction support; appetite control in some users.

**Dosing:** 250–500 mcg daily; split AM and pre-workout or pre-bed. 5 days on, 2 off or daily.

**Cycle:** 8–12 weeks.

**Administration:** Subcutaneous.

**Reconstitution:** 5 mg vial + 2.5 mL BW → 1 unit = 20 mcg.

**Stacks:** Pairs with GLP-1 class for appetite; add cardio.

**Cautions:** Mild; avoid if pregnant or nursing.

---

### L-Carnitine (Injectable)

**Overview:** Amino acid derivative that shuttles fatty acids into mitochondria for oxidation.

**Benefits:** Endurance, fatty acid utilization, pump.

**Dosing:** 200–500 mg IM or deep subq pre-workout; 3–5 days per week.

**Cycle:** 4–8 weeks.

**Administration:** IM preferred (ventrogluteal, deltoid).

**Reconstitution:** Often provided in solution; if powdered, reconstitute per supplier.

**Stacks:** GLP-1s, yohimbine (fasted AM), caffeine. Hydrate well.

**Cautions:** Injection site irritation; do not exceed osmolarity limits.

---

## Growth Hormone Axis — GHRH and Secretagogues

### CJC-1295 (no DAC)

**Overview:** GHRH analog; short half-life; used with a GHRP for pulsatile GH release.

**Benefits:** Sleep quality, recovery, fat loss support, IGF-1 increase.

**Dosing:** 100 mcg 1–3 times daily; common stack: CJC-1295 (no DAC) 100 mcg + Ipamorelin 100 mcg AM and pre-bed.

**Cycle:** 8–12 weeks.

**Administration:** Subcutaneous.

**Reconstitution:** 2 mg vial + 2 mL BW → 1 unit = 1 mcg.

**Stacks:** Ipamorelin, GHRP-2/6, fasting window pre-injection for best pulse.

**Cautions:** Carpal tunnel-like symptoms if IGF rises too high.

---

### CJC-1295 (DAC)

**Overview:** Long-acting GHRH analog (Drug Affinity Complex).

**Benefits:** Sustained IGF-1 elevation; convenient weekly dosing.

**Dosing:** 1–2 mg once weekly or split twice weekly.

**Cycle:** 8–12 weeks.

**Administration:** Subcutaneous.

**Reconstitution:** 2 mg vial + 2 mL BW → 1 unit = 1 mcg. Inject mg-levels using insulin syringe units math.

**Stacks:** Avoid stacking with other GH-raising agents if edema occurs.

**Cautions:** Water retention, numbness, fatigue possible.

---

### Ipamorelin

**Overview:** Selective ghrelin receptor agonist (GHRP) with minimal cortisol or prolactin effect.

**Benefits:** Pulsatile GH release; recovery and sleep support.

**Dosing:** 100–300 mcg 1–3 times daily; often 100 mcg AM and pre-bed.

**Cycle:** 8–12 weeks.

**Administration:** Subcutaneous.

**Reconstitution:** 2 mg vial + 2 mL → 1 unit = 1 mcg.

**Stacks:** CJC-1295 no DAC for synergy.

**Cautions:** Dizziness if injected fasted in some users.

---

### GHRP-2

**Overview:** Ghrelin receptor agonist; stronger but more side effects vs ipamorelin.

**Benefits:** GH pulse, appetite increase.

**Dosing:** 100–200 mcg 1–3x daily.

**Cycle:** 6–8 weeks.

**Administration:** Subcutaneous.

**Reconstitution:** 5 mg + 2.5 mL → 1 unit = 20 mcg.

**Stacks:** CJC-1295 no DAC.

**Cautions:** May raise cortisol and prolactin; water retention.

---

### GHRP-6

**Overview:** Ghrelin receptor agonist with strong hunger drive.

**Benefits:** GH pulse, appetite for bulking.

**Dosing:** 100–200 mcg 1–3x daily.

**Cycle:** 6–8 weeks.

**Administration:** Subcutaneous.

**Reconstitution:** 5 mg + 2.5 mL → 1 unit = 20 mcg.

**Stacks:** CJC-1295 no DAC.

**Cautions:** Hunger spikes; watch body fat gain.

---

### Hexarelin

**Overview:** Potent GHRP; high GH pulse but desensitizes quickly.

**Benefits:** Strength, recovery in short runs.

**Dosing:** 50–100 mcg 1–2x daily for 2–4 weeks; then break.

**Cycle:** Short bursts due to receptor desensitization.

**Administration:** Subcutaneous.

**Reconstitution:** 2 mg + 2 mL → 1 unit = 1 mcg.

**Stacks:** CJC-1295 no DAC.

**Cautions:** May impact lipids and prolactin.

---

### Sermorelin

**Overview:** GHRH analog; similar to CJC no DAC.

**Benefits:** GH/IGF support with low sides.

**Dosing:** 100–300 mcg pre-bed.

**Cycle:** 8–12 weeks.

**Administration:** Subcutaneous.

**Reconstitution:** 2 mg + 2 mL → 1 unit = 1 mcg.

**Stacks:** Ipamorelin.

**Cautions:** Mild flushing.

---

### Tesamorelin

**Overview:** GHRH analog FDA-approved for HIV-associated lipodystrophy; reduces visceral fat.

**Benefits:** Visceral fat reduction; IGF rise; possible sleep benefits.

**Dosing:** 2 mg subq daily (clinical); research protocols sometimes 1 mg daily.

**Cycle:** 8–12 weeks or longer with monitoring.

**Administration:** Subcutaneous.

**Reconstitution:** 2 mg + 2 mL → 1 unit = 1 mcg.

**Stacks:** Lifestyle changes to maintain fat loss.

**Cautions:** Injection site reactions; tingling; contraindications similar to GH.

---

### Somatropin (HGH)

**Overview:** Recombinant human growth hormone.

**Benefits:** Fat loss, recovery, joint comfort, IGF-mediated effects.

**Dosing:** 1–2 IU daily for wellness; 3–6 IU advanced users, split dosing.

**Cycle:** 12+ weeks.

**Administration:** Subcutaneous.

**Reconstitution:** Common 10 IU vial + 1 mL → 1 IU per 0.1 mL.

**Stacks:** Insulin sensitivity support (steps, metformin).

**Cautions:** Edema, carpal tunnel symptoms, insulin resistance at high doses.

---

## IGF Axis and Hypertrophy

### IGF-1 LR3

**Overview:** Long R3 IGF-1; resists binding proteins; longer activity.

**Benefits:** Nutrient partitioning, pumps, potential lean mass support.

**Dosing:** 20–60 mcg post-workout IM or subq in trained muscle, 3–5x weekly.

**Cycle:** 4–6 weeks.

**Administration:** IM or subq.

**Reconstitution:** 1 mg + 2 mL → 1 unit = 5 mcg.

**Stacks:** PEG-MGF alternating days.

**Cautions:** Hypoglycemia risk; start low.

---

### IGF-1 DES

**Overview:** Short-acting IGF-1 variant; site specific.

**Benefits:** Local hypertrophy signaling.

**Dosing:** 20–60 mcg pre or post-workout into target muscle, 3–5x weekly.

**Cycle:** 4–6 weeks.

**Administration:** IM or subq intramuscular region.

**Reconstitution:** 1 mg + 2 mL → 1 unit = 5 mcg.

**Stacks:** PEG-MGF or GH secretagogues.

**Cautions:** Hypoglycemia, jaw or hand aches.

---

### PEG-MGF

**Overview:** Pegylated mechano growth factor; longer half-life than MGF.

**Benefits:** Recovery and satellite cell activation support.

**Dosing:** 100–200 mcg 2–3x weekly post-workout.

**Cycle:** 4–6 weeks.

**Administration:** Subcutaneous.

**Reconstitution:** 2 mg + 2 mL → 1 unit = 1 mcg.

**Stacks:** Alternate with IGF-1 LR3.

**Cautions:** Water retention in some users.

---

### MGF (non-PEG)

**Overview:** Short-acting mechano growth factor.

**Benefits:** Acute recovery signaling.

**Dosing:** 100–200 mcg post-workout in trained muscle.

**Cycle:** 4 weeks.

**Administration:** IM or subq near muscle.

**Reconstitution:** 2 mg + 2 mL → 1 unit = 1 mcg.

**Stacks:** Use on different days than IGF-1 LR3.

**Cautions:** Short half-life requires timing.

---

## Tissue Repair and Anti-Inflammatory

### BPC-157

**Overview:** Gastric peptide that promotes angiogenesis and tendon, gut, and ligament healing in animal data.

**Benefits:** GI protection, tendon and joint recovery, anti-inflammatory effects.

**Dosing:** 250–500 mcg daily subq near injury or 250 mcg twice daily; oral capsules used by some.

**Cycle:** 4–8 weeks.

**Administration:** Subcutaneous; oral possible from some vendors.

**Reconstitution:** 5 mg + 2.5 mL → 1 unit = 20 mcg.

**Stacks:** TB-500; collagen and vitamin C; mechanical loading.

**Cautions:** Limited human clinical data.

---

### TB-500 (Thymosin Beta-4 Fragment)

**Overview:** Actin-binding peptide promoting cell migration and healing.

**Benefits:** Soft tissue healing, recovery, reduced inflammation.

**Dosing:** 2–5 mg weekly for 4–6 weeks (loading), then 2–5 mg monthly (maintenance).

**Cycle:** 6–10 weeks for loading.

**Administration:** Subcutaneous.

**Reconstitution:** 5 mg + 2.5 mL → 1 unit = 20 mcg.

**Stacks:** BPC-157 for synergy.

**Cautions:** Possible fatigue; keep injections sterile.

---

### KPV (Lys-Pro-Val)

**Overview:** Alpha-MSH tripeptide fragment; anti-inflammatory and GI barrier support.

**Benefits:** IBD symptoms, skin inflammation, general recovery (anecdotal).

**Dosing:** 250–500 mcg daily oral or subq; topical for dermatology.

**Cycle:** 4–8 weeks.

**Administration:** Subq, oral, or topical.

**Reconstitution:** 5 mg + 2.5 mL → 1 unit = 20 mcg.

**Stacks:** BPC-157 for GI.

**Cautions:** Limited human trials.

---

### GHK-Cu

**Overview:** Copper peptide complex that supports collagen synthesis and skin/hair health.

**Benefits:** Skin quality, wound healing, hair support.

**Dosing:** Topical serum nightly; injectable protocols 100–200 mcg subq near area 3x weekly.

**Cycle:** 8–12 weeks.

**Administration:** Topical or subq.

**Reconstitution:** 2 mg + 2 mL → 1 unit = 1 mcg.

**Stacks:** Microneedling (low depth) topically; vitamin C alternating nights.

**Cautions:** Copper sensitivity in rare cases.

---

## Neuro and Mood

### Semax

**Overview:** ACTH(4–10) analog; nootropic and neuroprotective properties in Russian literature.

**Benefits:** Focus, memory, stress resistance.

**Dosing:** 300–600 mcg total daily intranasal divided into 2–3 doses for 10–14 days.

**Cycle:** 2 weeks on, 2 weeks off pattern common.

**Administration:** Intranasal; some subq use.

**Reconstitution:** If solution, store refrigerated; if powder, reconstitute with sterile saline per vendor.

**Stacks:** Selank for anxiolysis.

**Cautions:** Irritation of nasal mucosa.

---

### Selank

**Overview:** Tuftsin analog; anxiolytic without sedation per Russian studies.

**Benefits:** Reduced anxiety, calm focus.

**Dosing:** 300–600 mcg total daily intranasal divided 2–3 times.

**Cycle:** 2 weeks on, 2 weeks off.

**Administration:** Intranasal.

**Reconstitution:** If solution, store refrigerated; if powder, reconstitute with sterile saline per vendor.

**Stacks:** Semax; magnesium glycinate at night.

**Cautions:** Mild nasal irritation.

---

### Dihexa

**Overview:** Small peptide that may enhance synaptogenesis in animal models.

**Benefits:** Focus and memory support (anecdotal).

**Dosing:** 5–20 mg oral daily reported in forums; topical 10–20 mg to neck also reported.

**Cycle:** 4–8 weeks then reassess.

**Administration:** Oral or topical.

**Reconstitution:** Often provided as capsules or solution.

**Stacks:** Semax or Noopept (non-peptide).

**Cautions:** Human data limited; start low.

---

## Sexual Function and Pigmentation

### Melanotan II (MT-2)

**Overview:** Melanocortin receptor agonist; increases melanin and libido.

**Benefits:** Tanning and libido support.

**Dosing:** Loading: 250–500 mcg daily for 1–2 weeks; Maintenance: 250–500 mcg 2–3x weekly.

**Cycle:** As needed.

**Administration:** Subcutaneous.

**Reconstitution:** 10 mg + 2 mL → 1 unit = 50 mcg.

**Stacks:** PT-141 for sexual function.

**Cautions:** Nausea, flushing; darkening of moles; avoid with melanoma history.

---

### PT-141 (Bremelanotide)

**Overview:** Melanocortin agonist for arousal; FDA nasal version exists.

**Benefits:** Sexual arousal in men and women.

**Dosing:** 1.25–2.5 mg subq as needed; intranasal 7–10 sprays total across nostrils in some research protocols.

**Cycle:** As needed with 24+ hr spacing.

**Administration:** Subq or intranasal.

**Reconstitution:** 10 mg + 2 mL → 1 unit = 50 mcg.

**Stacks:** MT-2 for tanning-libido combo.

**Cautions:** Nausea, flushing, transient BP changes.

---

## Immune and Endocrine Modulators

### Thymosin Alpha-1 (Talpha-1)

**Overview:** Immune modulator peptide.

**Benefits:** Immune balance and resilience.

**Dosing:** 1.6 mg twice weekly for 6–12 weeks is common in literature.

**Cycle:** 6–12 weeks.

**Administration:** Subcutaneous.

**Reconstitution:** 2 mg + 2 mL → 1 unit = 1 mcg.

**Stacks:** BPC-157, vitamin D, zinc for immune protocol.

**Cautions:** Generally well tolerated; monitor if autoimmune conditions present.

---

### Epithalon (Epitalon)

**Overview:** Synthetic tetrapeptide based on epithalamin; studied for telomerase activation.

**Benefits:** Telomere maintenance, potential anti-aging and sleep cycle regulation.

**Dosing:** 5–10 mg daily for 10–20 days; repeat cycle every 4–6 months.

**Cycle:** Short burst cycles with long breaks.

**Administration:** Subcutaneous or IV.

**Reconstitution:** 10 mg + 2 mL → 1 unit = 50 mcg.

**Stacks:** NAD+, antioxidants for longevity stack.

**Cautions:** Limited human trial data; generally well tolerated.

---

### NAD+ (Nicotinamide Adenine Dinucleotide)

**Overview:** Essential coenzyme for cellular energy and DNA repair; levels decline with age.

**Benefits:** Cellular energy, sirtuin activation, DNA repair, mental clarity.

**Dosing:** 25–100 mg subq twice weekly; escalate gradually over weeks.

**Cycle:** 12–14+ weeks; ongoing protocols exist.

**Administration:** Subcutaneous or IV infusion.

**Reconstitution:** Follow vendor-specific instructions based on vial size.

**Stacks:** SS-31 for mitochondrial synergy; MOTS-c for metabolic activation; resveratrol for sirtuin amplification.

**Cautions:** Flushing and nausea at higher doses; start low and titrate.

---

### Summary Table — Quick Reference

| Category | Peptides | Key Benefit |
|----------|----------|-------------|
| GLP-1 / Weight | Semaglutide, Tirzepatide, Retatrutide, AOD-9604, L-Carnitine | Appetite control, fat loss |
| GH Axis | CJC-1295, Ipamorelin, GHRP-2/6, Hexarelin, Sermorelin, Tesamorelin, HGH | GH release, recovery, sleep |
| IGF / Hypertrophy | IGF-1 LR3, IGF-1 DES, PEG-MGF, MGF | Muscle growth, nutrient partitioning |
| Tissue Repair | BPC-157, TB-500, KPV, GHK-Cu | Healing, anti-inflammatory, skin |
| Neuro / Mood | Semax, Selank, Dihexa | Focus, memory, anxiety reduction |
| Sexual / Pigmentation | Melanotan II, PT-141 | Libido, tanning |
| Immune / Endocrine | Thymosin Alpha-1, Epithalon, NAD+ | Immune support, longevity |

---

*This article is for research and educational purposes only. All compounds discussed are intended for laboratory research use. Consult relevant regulatory guidelines before any experimental application.*
    `
  },
  {
    slug: "mitochondrial-enhancement-protocol",
    title: "The 14-Week Mitochondrial Enhancement Protocol: SS-31, MOTS-c & NAD+",
    excerpt: "A detailed analysis of a sequential 14-week protocol combining SS-31, MOTS-c, and NAD+ to target mitochondrial health, metabolic function, and longevity pathways.",
    date: "February 20, 2026",
    category: "Longevity",
    image: mitochondrialProtocolCover,
    content: `
### Introduction

This 14-week protocol is designed to sequentially target mitochondrial health and metabolic function using three interventions: **SS-31**, **MOTS-c**, and **NAD+**. Each compound is introduced in a specific order and timeframe to optimize their individual benefits and exploit potential synergistic effects. The overarching goal is to improve mitochondrial energy production, enhance metabolic health, and promote longevity-related pathways.

---

### Protocol Schedule Overview

| Week | SS-31 | MOTS-c | NAD+ |
|------|-------|--------|------|
| Week 1–2 | — | — | 25 mg twice/week |
| Week 3–4 | 4 mg daily | — | 50 mg twice/week |
| Week 5–8 | 4 mg daily | — | 100 mg twice/week |
| Week 9–14 | — | 5 mg 3×/week | 100 mg twice/week |

---

### SS-31: Mitochondria-Targeted Peptide (Elamipretide)

SS-31 is a cell-permeable tetrapeptide that selectively concentrates in the inner mitochondrial membrane by binding to **cardiolipin**, a unique phospholipid critical for electron transport chain (ETC) function. By stabilizing ETC supercomplexes, SS-31 improves electron transfer efficiency and preserves ATP production while minimizing reactive oxygen species (ROS) generation.

**Key mechanisms:**
- Scavenges mitochondrial ROS and prevents oxidative damage
- Improves mitochondrial bioenergetics by modulating cytochrome c–cardiolipin interactions
- Inhibits opening of the mitochondrial permeability transition pore (mPTP)
- Enhances organ function in aging: 8 weeks of SS-31 in aged mice improved cardiac diastolic function and reduced oxidative stress to youthful levels

SS-31 is given during **weeks 3–8** (a 6-week window), as prolonged use beyond 4 weeks has not been formally studied in humans. This timeframe aligns with animal studies (4–8 weeks) that achieved significant mitochondrial improvements.

---

### MOTS-c: Mitochondrial-Derived Peptide

MOTS-c is a 16-amino acid peptide encoded in mitochondrial DNA (12S rRNA gene) that functions as a signaling molecule linking mitochondrial status to nuclear metabolism.

**Key mechanisms:**
- **AMPK activation**: Interferes with the folate cycle, causing AICAR accumulation that activates AMPK — a master energy sensor enhancing glucose uptake, fatty-acid oxidation, and mitochondrial biogenesis
- **Nuclear gene regulation**: Translocates to the nucleus to regulate genes involved in metabolism and proteostasis
- **NAD+ elevation**: Raises intracellular NAD+ levels and acts via SIRT1 to exert metabolic effects
- **Anti-inflammatory action**: Reduces IL-6 levels and enhances antioxidant responses via Nrf2 activation

In animal studies, MOTS-c prevented obesity and insulin resistance in mice on high-fat diets. In older mice, intermittent MOTS-c (5 mg/kg thrice weekly) significantly enhanced physical performance and delayed age-related frailty. MOTS-c levels naturally decline ~20% with aging, making supplementation a compelling strategy.

MOTS-c is introduced during **weeks 9–14** after SS-31 has repaired the mitochondrial machinery, allowing cells to fully capitalize on MOTS-c's metabolic activation.

---

### NAD+ Supplementation: The Metabolic Backbone

NAD+ is a vital coenzyme acting as an electron carrier in redox reactions and a substrate for signaling enzymes (sirtuins, PARPs). NAD+ levels diminish with age due to reduced synthesis and increased consumption, leading to metabolic sluggishness and impaired DNA repair.

**Supplementation benefits:**
- Activates sirtuin enzymes (SIRT1, SIRT3) that regulate energy metabolism and genomic stability
- Improves mitochondrial function via SIRT3-mediated deacetylation of metabolic enzymes
- Enhances mental clarity, energy levels, and brain function
- Supports DNA repair mechanisms

**Dosage escalation rationale:**
- **Weeks 1–2**: 25 mg twice/week — allows acclimation and avoids side effects (flushing, nausea)
- **Weeks 3–4**: 50 mg twice/week — gradual increase as tolerance builds
- **Weeks 5–14**: 100 mg twice/week — therapeutic plateau maintained throughout

NAD+ is the only component spanning all 14 weeks, providing continuous metabolic support for both SS-31 and MOTS-c phases.

---

### The Three-Phase Sequential Strategy

**Phase 1 — Foundation (Weeks 1–2): NAD+ Loading**
Elevating NAD+ ensures cells have ample metabolic cofactor availability and activated sirtuin pathways from the outset. This "fuel priming" readies mitochondria for improvement.

**Phase 2 — Mitochondrial Repair (Weeks 3–8): SS-31 + NAD+**
With NAD+-dependent enzymes already more active, SS-31 directly targets mitochondria to reduce ROS and stabilize ETC function. Research in aged mice showed combined NAD+ and SS-31 treatment produced a **synergistic rejuvenating effect** on heart metabolism that exceeded either compound alone.

**Phase 3 — Metabolic Enhancement (Weeks 9–14): MOTS-c + NAD+**
After mitochondria have been revitalized by SS-31, MOTS-c activates AMPK to push the system to higher performance. The AMPK–SIRT1 positive feedback loop is amplified by maintained NAD+ levels, driving improvements in glucose handling, insulin sensitivity, and physical endurance.

---

### Synergistic Effects

**SS-31 + NAD+ (Mitochondrial Synergy)**
SS-31 preserves ETC function while NAD+ provides NADH fuel. Because SS-31 reduces oxidative damage, less NAD+ is diverted to PARP enzymes for DNA repair, conserving NAD+ pools for productive metabolism. Combined treatment in aged hearts restored youthful energy dynamics better than either alone.

**MOTS-c + NAD+ (Metabolic Synergy)**
MOTS-c triggers AMPK, AMPK boosts NAD+ via NAMPT upregulation, and high NAD+ activates sirtuins that complement AMPK effects. With NAD+ already elevated, SIRT1 is primed when MOTS-c arrives — producing stronger metabolic effects than MOTS-c alone.

**SS-31 → MOTS-c (Sequential Complementarity)**
By improving mitochondrial capacity first, SS-31 enhances responsiveness to MOTS-c's metabolic demands. When AMPK activation increases energy requirements, repaired mitochondria can meet that demand with higher efficiency and resilience.

---

### Why This Sequence Matters

The order **NAD+ → SS-31 → MOTS-c** follows a logical progression: first repair the engine (mitochondria), then step on the gas pedal (AMPK/metabolic activation). An alternate sequence — activating metabolism before repairing mitochondria — would be like revving a broken engine, potentially producing excess ROS without achieving desired energy output.

All three interventions together target the **"mitochondrial triangle" of healthy aging**: mitochondrial function, metabolic signaling, and cellular maintenance. The expected result is a multiplicative effect where combined treatment best recapitulates youthful metabolic states.

---

### Key Takeaways

1. **Sequential approach** avoids overloading the body and allows each compound's effects to unfold fully
2. **NAD+ dose escalation** ensures safety, tolerance, and optimal utilization
3. **SS-31's 6-week window** captures mitochondrial benefits within prudent safety margins
4. **MOTS-c after SS-31** leverages repaired mitochondria for maximum metabolic enhancement
5. **Combined synergies** produce greater results than any single intervention alone

*This article is for research and educational purposes only. All compounds discussed are intended for laboratory research use. Consult relevant regulatory guidelines before any experimental application.*
    `
  },
  {
    slug: "retatrutide-research",
    title: "Retatrutide in Research: Stability, Storage, and Experimental Optimization",
    excerpt: "Explore the stability, storage, and experimental best practices for retatrutide peptide in laboratory research.",
    date: "February 15, 2026",
    category: "Peptide Resources",
    image: retatrutideCover,
    content: `
### 1. Introduction
Retatrutide is a multi-receptor peptide examined in advanced metabolic research models. It is studied for its interaction with GLP-1, GIP, and glucagon receptor pathways and its role in complex endocrine signaling systems.

Because retatrutide is a peptide-based compound, laboratory handling, storage conditions, and preparation methods play an important role in maintaining structural integrity and ensuring consistent experimental outcomes.

### 2. Retatrutide Peptide: Mechanism and Research Applications
Retatrutide is characterized as a triple-agonist peptide targeting:
- GLP-1 receptors
- GIP receptors
- Glucagon receptors

In laboratory systems, researchers investigate retatrutide’s role in:
- Appetite pathway modulation
- Glucose-dependent insulin signaling
- Energy expenditure mechanisms
- Integrated endocrine coordination
- Body composition research models

### 3. Importance of Stability in Peptide-Based Research
Peptides are structurally sensitive molecules composed of amino acid chains that rely on proper folding and environmental stability to maintain receptor-binding capability. Inconsistent storage conditions, repeated temperature changes, or moisture exposure can influence molecular integrity.

### 4. Retatrutide Storage and Handling: Format Comparison
**4.1 Vial Format (Lyophilized Powder)**
In vial form, retatrutide is typically provided as a freeze-dried (lyophilized) powder. Lyophilization removes moisture, significantly improving stability during storage and transport.

**4.2 Pre-Filled Pen Format (Solution)**
In pre-filled pen format, retatrutide is supplied as a stabilized solution. This format removes preparation variability and may be preferred in laboratory settings requiring standardized solution conditions.

### 5. Experimental Optimization: Best Practices
- Maintaining stable temperature conditions
- Avoiding unnecessary freeze–thaw cycles
- Using sterile handling techniques
- Ensuring consistent preparation protocols
- Documenting storage conditions across experimental batches
    `
  },
  {
    slug: "what-is-orforglipron",
    title: "What is Orforglipron?",
    excerpt: "Orforglipron is a small-molecule compound examined in experimental research focused on GLP-1 receptor signaling.",
    date: "February 12, 2026",
    category: "Metabolic Research",
    image: orforglipronCover,
    content: `
### Research overview
Orforglipron is an orally active small-molecule compound studied in experimental models examining GLP-1 receptor–mediated metabolic and energy-regulation signaling. Unlike peptide-based GLP-1 analogs, Orforglipron is designed as a non-peptide structure.

### Molecular classification and structure
Orforglipron belongs to the class of non-peptide GLP-1 receptor agonists, representing a distinct category from traditional peptide-based incretin mimetics. Its molecular design allows selective interaction with the glucagon-like peptide-1 receptor while maintaining chemical stability suitable for oral experimental formulations.

### Mechanism of action in research models
In experimental systems, Orforglipron is examined for its high-affinity interaction with the orthosteric binding site of the GLP-1 receptor. Upon receptor binding, laboratory studies show activation of G-protein–mediated intracellular signaling, particularly pathways associated with cyclic AMP (cAMP) generation.

### Biased signaling and receptor dynamics
Biased agonism is a key reason Orforglipron attracts scientific interest. In laboratory studies, reduced β-arrestin recruitment is associated with altered receptor internalization and signaling persistence.
    `
  },
  {
    slug: "cellular-homeostasis",
    title: "Cellular Homeostasis & Health Maintenance Research",
    excerpt: "An overview of experimental research exploring cellular balance, metabolic regulation, and antioxidant systems.",
    date: "February 10, 2026",
    category: "Homeostasis",
    image: homeostasisCover,
    content: `
### Introduction
In experimental biology, long-term health maintenance is increasingly studied through the lens of cellular homeostasis — the ability of biological systems to preserve balance, stability, and function over time.

### Redox Balance and Oxidative Stress Regulation
Oxidative stress is a central factor studied in aging and cellular dysfunction research. In laboratory models, excessive reactive oxygen species (ROS) are associated with impaired signaling, mitochondrial strain, and structural degradation over time.

### Metabolic Regulation and Cellular Energy Availability
Cellular health depends heavily on efficient energy regulation. Experimental studies frequently explore how metabolic signaling pathways influence glucose handling, NAD⁺ availability, and mitochondrial efficiency under baseline conditions.

### Structural Integrity and Extracellular Matrix Signaling
Long-term tissue health requires continuous maintenance of structural components such as the extracellular matrix and connective tissue architecture.
    `
  },
  {
    slug: "what-is-ghk-cu",
    title: "What is GHK-Cu? - A Copper Peptide in Tissue Remodeling",
    excerpt: "An introduction to GHK-Cu as a research peptide studied in models examining cellular communication.",
    date: "February 8, 2026",
    category: "Cosmetic Peptides",
    image: ghkCuCover,
    content: `
### GHK-Cu Overview
GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring peptide–copper complex detected in human plasma, saliva, and urine. In experimental systems, GHK-Cu is studied for its ability to transport bioavailable copper into cells.

### Fibroblast Activity and Extracellular Matrix Research
One of the most studied research areas involving GHK-Cu is its interaction with fibroblasts—connective tissue cells responsible for producing and maintaining the extracellular matrix (ECM).

### Antioxidant and Inflammatory Signaling Modulation
GHK-Cu is frequently examined in oxidative stress research due to its role as a copper carrier for antioxidant enzymes. In experimental systems, it supports copper-dependent superoxide dismutase (SOD) activity.

### Angiogenesis and Vascular Research
GHK-Cu is also investigated in angiogenesis-focused research models. During early phases of tissue injury, this peptide can be released from matrix-associated proteins and participate in signaling cascades.
    `
  },
  {
    slug: "bpc157-tb500-synergy",
    title: "BPC 157 TB 500: How These Peptides Work Together",
    excerpt: "Explore how BPC-157 and TB-500 are studied in preclinical research, including their distinct mechanisms.",
    date: "February 5, 2026",
    category: "Healing & Repair",
    image: bpcTbCover,
    content: `
### Introduction
Peptide research has seen a surge of interest in compounds like BPC-157 and TB-500 for their remarkable regenerative and healing potential. BPC-157 and TB-500 each act on different biological pathways involved in tissue repair.

### What is BPC-157?
BPC-157 (Body Protection Compound-157) is a pentadecapeptide originally isolated from a protein found in human gastric juice. In laboratory studies, BPC-157 has shown a broad range of regenerative effects on various tissues.

### What is TB-500?
TB-500 is the research name for a synthetic fragment of thymosin beta-4 (Tβ4), a naturally occurring protein involved in cell migration and wound healing.

### Synergistic Potential
Despite their distinct origins, BPC-157 and TB-500 have complementary roles in the healing process. Researchers are interested in studying them together because each peptide targets different, but equally critical, aspects of tissue repair.
    `
  },
  {
    slug: "nad-longevity",
    title: "NAD+ and Longevity: Unlocking the Science of Anti-Aging",
    excerpt: "Discover how NAD+, autophagy, and senescence shape the body's aging process and cellular renewal.",
    date: "February 1, 2026",
    category: "Longevity",
    image: nadLongevityCover,
    content: `
### Unlocking the Science
Imagine your body as a bustling metropolis, where cells are the citizens, constantly building and repairing. Longevity is the ultimate goal—living longer, healthier.

### The Autophagy Revolution
Picture autophagy as your cells' superhero janitor, devouring damaged parts to recycle them into fresh energy. This process, triggered by stress like fasting or exercise, is a cornerstone of longevity.

### Senescence: The Zombie Cells
Senescence is the villain twist: cells that stop dividing but linger like undead zombies, secreting SASP—a toxic cocktail of signals causing inflammation and accelerated aging.

### NAD+ Fuel
NAD+ fuels sirtuins, anti-aging proteins that enhance DNA repair, autophagy, and resistance to senescence. Research into NAD+ supplementation focuses on its potential to restore cellular energy levels.
    `
  }
];
